AJP - Heart and Circulatory Physiology, Vol 253, Issue 6 1449-H1455, Copyright © 1987 by American Physiological Society

ARTICLES

Atrial natriuretic peptide transcription, storage, and release in rats with myocardial infarction

R. E. Mendez, J. M. Pfeffer, F. V. Ortola, K. D. Bloch, S. Anderson, J. G. Seidman and B. M. Brenner
Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

To study the role of atrial natriuretic peptide (ANP) in chronic heart failure, ANP synthesis, storage, and release were examined by measuring atrial ANP messenger ribonucleic acid (mRNA) levels and atrial and plasma ANP concentrations in rats with myocardial infarction produced by coronary artery ligation. Three groups were defined as the following: 1) controls, sham-operated, or operated, but noninfarcted; 2) moderate infarcts, involving 5-30% of the left ventricular circumference; and 3) large infarcts (greater than or equal to 30%). In addition, to determine a possible modulation by dietary Na intake on ANP levels in heart failure, plasma immunoreactive ANP (iANP) levels were measured in rats with and without infarcts given low, regular, or high Na intake for 2 wk, by which time all groups were in neutral balance. Plasma iANP levels varied directly with increasing infarct and atrial sizes, irrespective of Na intake. In contrast, atrial ANP concentration varied inversely with increasing infarct size. The ANP mRNA content index, a measure of total atrial ANP mRNA, was significantly increased in rats with large infarcts compared with control rats. These results indicate that in rats with myocardial infarction, the severity of left ventricular dysfunction, as inferred from infarct size, but not chronic Na intake, is the primary determinant of the extent of activation of the ANP system. Elevated circulating ANP levels are maintained through enhanced atrial synthesis and release. ANP may thus play an important role in the hemodynamic and renal adaptations to chronic heart failure.

This article has been cited by other articles:

				N. S. Dhalla, M. R. Dent, P. S. Tappia, R. Sethi, J. Barta, and R. K. Goyal Subcellular Remodeling as a Viable Target for the Treatment of Congestive Heart Failure Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2006; 11(1): 31 - 45. [Abstract] [PDF]

				L. W. Stanton, L. J. Garrard, D. Damm, B. L. Garrick, A. Lam, A. M. Kapoun, Q. Zheng, A. A. Protter, G. F. Schreiner, and R. T. White Altered Patterns of Gene Expression in Response to Myocardial Infarction Circ. Res., May 12, 2000; 86(9): 939 - 945. [Abstract] [Full Text] [PDF]

				C. F. McTiernan, B. H. Lemster, C. Frye, S. Brooks, A. Combes, and A. M. Feldman Interleukin-1ß Inhibits Phospholamban Gene Expression in Cultured Cardiomyocytes Circ. Res., October 19, 1997; 81(4): 493 - 503. [Abstract] [Full Text]

				M. Petrou, D. G. Wynne, K. R. Boheler, and M. H. Yacoub Clenbuterol Induces Hypertrophy of the Latissimus Dorsi Muscle and Heart in the Rat With Molecular and Phenotypic Changes Circulation, November 1, 1995; 92(9): 483 - 489. [Abstract] [Full Text]

				N. Hama, H. Itoh, G. Shirakami, O. Nakagawa, S.-i. Suga, Y. Ogawa, I. Masuda, K. Nakanishi, T. Yoshimasa, Y. Hashimoto, et al. Rapid Ventricular Induction of Brain Natriuretic Peptide Gene Expression in Experimental Acute Myocardial Infarction Circulation, September 15, 1995; 92(6): 1558 - 1564. [Abstract] [Full Text]

				S. Kim, M. Kawamura, H. Wanibuchi, K. Ohta, A. Hamaguchi, T. Omura, T. Yukimura, K. Miura, and H. Iwao Angiotensin II Type 1 Receptor Blockade Inhibits the Expression of Immediate-Early Genes and Fibronectin in Rat Injured Artery Circulation, July 1, 1995; 92(1): 88 - 95. [Abstract] [Full Text]

				A. F. M. Moorman, J. L. M. Vermeulen, M. U. Koban, K. Schwartz, W. H. Lamers, and K. R. Boheler Patterns of Expression of Sarcoplasmic Reticulum Ca2+-ATPase and Phospholamban mRNAs During Rat Heart Development Circ. Res., April 1, 1995; 76(4): 616 - 625. [Abstract] [Full Text]